IOVA Key Statistics, Chart & Performance
The current stock price of IOVA is 2.45 USD. In the past month the price increased by 8.41%. In the past year, price decreased by -61.72%.
IOVA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About IOVA
Company Profile
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 838 full-time employees. The company went IPO on 2008-06-20. The company is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its product, Amtagvi, is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The company is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. The company also develops therapies, such as genetically modified TIL cell therapy and cytokines for use in the TIL cell therapy regimen.
Company Info
IOVANCE BIOTHERAPEUTICS INC
825 Industrial Road, 4th Floor
San Carlos CALIFORNIA 94070 US
CEO: Maria Fardis
Employees: 838
Phone: 16502607120
IOVANCE BIOTHERAPEUTICS INC / IOVA FAQ
What does IOVA do?
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 838 full-time employees. The company went IPO on 2008-06-20. The company is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its product, Amtagvi, is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The company is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. The company also develops therapies, such as genetically modified TIL cell therapy and cytokines for use in the TIL cell therapy regimen.
What is the current price of IOVA stock?
The current stock price of IOVA is 2.45 USD. The price decreased by -6.13% in the last trading session.
Does IOVANCE BIOTHERAPEUTICS INC pay dividends?
IOVA does not pay a dividend.
What is the ChartMill technical and fundamental rating of IOVA stock?
IOVA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for IOVA stock?
The Revenue of IOVANCE BIOTHERAPEUTICS INC (IOVA) is expected to grow by 58.86% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
How many employees does IOVANCE BIOTHERAPEUTICS INC have?
IOVANCE BIOTHERAPEUTICS INC (IOVA) currently has 838 employees.
What is the Short Interest ratio of IOVANCE BIOTHERAPEUTICS INC (IOVA) stock?
The outstanding short interest for IOVANCE BIOTHERAPEUTICS INC (IOVA) is 32.81% of its float.
IOVA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to IOVA. When comparing the yearly performance of all stocks, IOVA is a bad performer in the overall market: 87.16% of all stocks are doing better.
IOVA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IOVA. IOVA has a bad profitability rating. Also its financial health evaluation is rather negative.
IOVA Financial Highlights
Over the last trailing twelve months IOVA reported a non-GAAP Earnings per Share(EPS) of -1.19. The EPS increased by 20.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.94% | ||
| ROE | -56.62% | ||
| Debt/Equity | 0 |
IOVA Forecast & Estimates
18 analysts have analysed IOVA and the average price target is 8.52 USD. This implies a price increase of 247.63% is expected in the next year compared to the current price of 2.45.
For the next year, analysts expect an EPS growth of 17% and a revenue growth 58.86% for IOVA